25 Phase II Trial of Sacituzumab Tirumotecan in Patients with SMARCB1-Deficient Renal Medullary Carcinoma Previously Treated with at Least One Prior Line of Therapy: STaRMC Trial (NCT07438626) - Pavlos Msaouel; Rebecca Slack-Tidwell; Rahul Sheth; Nizar Tannir (The Oncologist, 2026)